Theravance IPO Would Fund Phase III Telavancin Antibiotic Trials

Phase I data for telavancin indicates non-inferiority to standard of care therapy. Theravance also has a broad collaborative agreement with GSK for long-acting beta-2 agonists for the treatment of COPD. Former Merck CEO Roy Vagelos is chairman of Theravance.